Results 241 to 250 of about 2,564,262 (308)

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Exploring individual biases in BCI research and users: Does gender matter? [PDF]

open access: yesFront Hum Neurosci
Herbert C   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy